Sunshine Biopharma (SBFM) Profit After Tax (2010 - 2026)

Sunshine Biopharma (SBFM) has 16 years of Profit After Tax data on file, last reported at -$1.5 million in Q1 2026.

• Quarterly Profit After Tax fell 31.93% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.4 million (down 66.54% YoY) and the FY2025 annual result came in at -$6.0 million, down 16.39% from the prior year.
• Profit After Tax rose to -$1.5 million in Q1 2026, from -$2.7 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$346163.0 in Q3 2024 to a low of -$23.3 million in Q4 2022.
• A 5-year average of -$2.6 million and a median of -$1.5 million in 2025 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax slumped 2915.57% — and 2023, when it jumped 96.75%.
• Tracing SBFM's Profit After Tax over 5 years: stood at -$23.3 million in 2022, then jumped by 96.75% to -$758468.0 in 2023, then plunged by 115.0% to -$1.6 million in 2024, then tumbled by 62.51% to -$2.7 million in 2025, then soared by 42.57% to -$1.5 million in 2026.
• The last three Profit After Tax figures came in at -$1.5 million (Q1 2026), -$2.7 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.